Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...

AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon ​to announce agreements ...

The populations of wealthy western nations are getting older and sicker, while emerging countries are demanding better ...

Danish pharma major Novo Nordisk has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide and semaglutide) injection, to be used ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

Seize the day with the freshest news you can use to help you conquer another active business day - from the team at BizNews ...

As Indian drug giants rush to export weight-loss drug semaglutide in countries that don’t have patent exclusivity, they face ...

UnitedHealth Group has had a tumultuous year, marred by poor performance and controversy. Eli Lilly has thrived as it's taken ...

Health-care companies ticked up as traders rotated back into higher risk sectors. Eli Lilly shares rose after the maker of weight-loss drugs filed for U.S. Food and Drug Administration approval of a ...

Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...